ANIX Anixa Biosciences Inc Insider Trading

CEO Amit Kumar purchases 21,000 shares of ANIX at $2.50; sixth buy at ticker with 5 of 5 prior ANIX trades well-timed at 90-day mark.

Amit Kumar, CEO of Anixa Biosciences, purchased 21,000 shares at $2.50 on 2026-06-12, increasing his holdings to 630.8K shares (+3.4% from 609.8K). This marks his sixth open-market purchase at this ticker. His prior five ANIX trades each demonstrated positive 90-day returns (ranging from +8.4% to +56.2%), and all five were well-timed entries. However, the current price of $2.48 sits -54.6% from the 52-week high, and the stock has declined -12.1% over the past 30 days and -14.2% over 90 days. Against this backdrop of recent weakness and unprofitable fundamentals ($-2.5M net income in the latest period), the consistency of his prior ANIX timing pattern (5 of 5 well-timed at 90 days) provides context for investor evaluation of this purchase's significance.

Director Baskies Arnold M bought 10,000 shares of ANIX at $3.04 on 2026-01-28 (8.0% stake increase to 135.0K shares).

Director Baskies Arnold M purchased 10,000 shares at $3.04, increasing his holdings to 135,000 shares, an 8.0% increase from pre-transaction levels. The current price of $3.10 is -40.6% from the 52-week high of $5.22 and down 24.9% over the past 90 days, placing the stock in a depressed position. His prior ANIX trades show mixed timing: two of three measurable outcomes showed positive 90-day returns (+29.8% and +1.9%), though one prior buy declined -25.1% over 90 days. The company remains unprofitable (net income of -$2.3M most recent quarter) with stalled revenue growth (0.0% annual growth), which constrains the fundamental backdrop for conviction assessment. This purchase follows his January 2025 buy at the same price point, but without additional context on transaction timing or agreement flags, the motivations remain opaque—only the price action relative to his recent history and the company's financial position are observable.

Director Titterton buys 10,000 ANIX shares at $3.08; holds 953.3K shares post-transaction.

Titterton Lewis H jr, a Director, purchased 10,000 shares of Anixa Biosciences at $3.08 on 2025-07-31, bringing his total holdings to 953.3K shares. This represents a modest 1.1% increase in his position. The transaction occurred at a price $0.18 below the current price of $3.26 and within the 52-week range of $2.13–$3.97. At the same-ticker level, Titterton's prior four measurable trades at ANIX delivered mixed results: only 1 of 4 prior buys showed positive 90-day returns, and his most recent purchase on 2025-07-11 remains unmeasurable. His cross-ticker track record shows stronger performance (73.33% 90-day win rate, avg 90d return +9.0%), but that does not account for his comparatively weaker performance at this specific security. The company remains unprofitable (net income $-2.8M) with stalled annual revenue growth at +0.0%, creating fundamental headwinds.

ANIX CEO buys 5,000 shares at $3.16; 2 peers also bought in past 14 days; stock -22.9% from 52-week high.

CEO Amit Kumar purchased 5,000 shares at $3.16 on 2025-07-30, expanding his stake to 579.9K shares. This buy occurred within a cluster pattern—two other insiders also purchased ANIX shares within the preceding 14 days—suggesting coordinated accumulation at depressed valuations. At his prior ANIX trades, Kumar achieved 90-day returns of +27.8%, +39.4%, and -15.5% respectively, with 2 of 3 prior purchases well-timed at the 90-day mark, indicating consistent success identifying entry points at this ticker. The current price of $3.06 sits -22.9% from the 52-week high of $3.97, and the company remains unprofitable with $-2.8M net income on quarterly revenue of $210.0K, making fundamental recovery a prerequisite for shareholder gains.

Director Baskies Arnold M buys 5,000 shares of ANIX at $3.39; part of 2-insider cluster buy in 14 days

Baskies Arnold M purchased 5,000 shares at $3.39 on 2025-07-18, increasing his holdings by 5,000 shares to 125,000 shares post-transaction. This buy occurs alongside a 2-other-insider cluster pattern within the past 14 days, suggesting coordinated director-level confidence. However, the company remains unprofitable with net income of $-2,790,000.00 against revenue of $210,000.00, and annual revenue growth is +0.0%, indicating financial headwinds. At the same ticker, the insider's prior buy on 2024-03-15 resulted in a 90-day return of -25.1%, and his cross-ticker track record shows a 90-day win rate of only 50.00%, suggesting mixed timing accuracy. The stock has risen 26.1% over 90 days but remains 13.6% below its 52-week high, leaving unclear whether this represents conviction in a turnaround or a continuation of inconsistent positioning.

Director Titterton Lewis H jr buys 10,000 ANIX shares at $3.14 amid stalled growth and losses

Titterton Lewis H jr, a director of Anixa Biosciences, purchased 10,000 shares at $3.14 on 2025-07-11, bringing his holdings to 943,334 shares. The purchase occurred as the stock trades at $3.20, down 4.2% over 30 days and 19.4% from its 52-week high of $3.97. Fundamentally, the company reported revenue of $210,000.00 in its latest quarter with a net loss of $-2,790,000.00, and annual revenue growth stands at +0.0%, signaling a stalled business trajectory. His same-ticker history at ANIX shows mixed outcomes: 2 of 5 prior buy transactions had positive 90-day returns, but the others declined 6–10% on a 90-day basis, reflecting inconsistent timing results at this particular security.

ANIX CEO Kumar Amit bought 5,000 shares at $3.15; stock -19.4% from 52-week high, company unprofitable with $-2.8M net income last year.

Amit purchased 5,000 shares at $3.15, adding to 574.9K shares held post-transaction, at a time when Anixa Biosciences is trading -19.4% from its 52-week high of $3.97 and the stock is down 4.2% over the prior 30 days. The company remains unprofitable with $-2.8M net income over its most recent full fiscal year and minimal revenue of $210.0K last quarter, signaling structural headwinds. Across his prior 4 ANIX trades, Amit's timing outcome is mixed: 2 of 3 measurable 90-day intervals were well-timed (buys on 2025-01-15 and 2024-06-07 saw subsequent gains of +27.8% and +39.4% respectively), but his trade on 2024-03-15 resulted in a -15.5% 90-day decline, indicating inconsistent accuracy in identifying recovery points even at this specific ticker. The current purchase into a depressed price within 90 days of his prior June 4 buy carries moderate insider credibility from his favorable historical returns, but the company's persistent unprofitability and zero annual revenue growth warrant scrutiny of whether this represents conviction or routine portfolio activity.

ANIX CEO buys 10,000 shares at $2.85; holdings now 569,925 shares. Stock -28.5% from 52-week high but +8.0% in 30 days.

CEO Amit Kumar purchased 10,000 shares of Anixa Biosciences on 2025-06-04 at $2.85, expanding his holdings to 569,925 shares (+1.8%). His prior two purchases at ANIX showed divergent timing outcomes: the January 2025 buy delivered 90-day gains of +27.8%, while the March 2024 buy resulted in 90-day losses of -15.5%, indicating inconsistent predictive value of his buy decisions at this ticker. The company is unprofitable with $-2.8M net income on quarterly revenue of $210.0K, and zero annual revenue growth, creating a speculative risk profile. Stock is currently $2.84, down -28.5% from the 52-week high of $3.97, though it has recovered +8.0% over the prior 30 days, leaving the timing and motivations of this purchase open to interpretation given the fundamental challenges and uneven pattern of his prior ANIX trades.

Director Baskies Arnold M bought 5,000 ANIX shares at $2.82; 3 other insiders also bought in past 14 days.

Director Baskies Arnold M purchased 5,000 shares at $2.82, increasing his holdings to 120,000 shares. This transaction is part of a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated or independent alignment on valuation at current levels. However, the company remains unprofitable with net income of $-3,277,000.00 in the latest quarter and zero annual revenue growth, while the stock is currently -35.3% from its 52-week high of $4.64. Arnold's prior two purchases at ANIX produced mixed results (30d returns of +2.9% and -12.7%, respectively), indicating inconsistent timing at this ticker.

Director Titterton Lewis H jr bought 3,000 shares at $2.94 avg (Jan 23–24); 2 other insiders also bought within 14 days; ANIX stock -43.3% from 52-week high.

Titterton Lewis H jr, a director at Anixa Biosciences, executed two separate purchases totaling 3,000 shares for $8,820.00 on January 23–24, 2025, at a blended average price of $2.94. The timing coincides with a cluster buy pattern in which 2 other insiders also purchased shares within the past 14 days. His prior trades at ANIX show a 2-of-2 well-timed pattern (both July 2024 purchases yielded positive 90-day returns of +22.3% and +29.7%), indicating consistent execution discipline at this ticker. However, the stock is currently trading at $2.78, down 43.3% from its 52-week high of $4.90, and the company reported near-zero revenue growth ($210,000 in the latest quarter) while posting a $-3.3M net loss, making it deeply unprofitable. The cluster buy activity by multiple insiders and the director's repeat accumulation despite deteriorating fundamentals merit closer scrutiny into whether recent developments have shifted the board's or management's conviction about near-term value.